Biohaven begins Phase III of rimegepant for acute migraine

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) began the first of 2 Phase III trials to evaluate 75 mg oral rimegepant (BHV-3000) to treat acute migraine.

The trial's co-primary endpoints are freedom from pain and demonstrated effect on patient's most bothersome symptom (nausea, photophobia or phonophobia) at 2 hours post-dosing. Safety will also be evaluated...